<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929395</url>
  </required_header>
  <id_info>
    <org_study_id>D0928</org_study_id>
    <secondary_id>NCI-2011-03481</secondary_id>
    <nct_id>NCT01929395</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery</brief_title>
  <official_title>A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2 Phase study. In the first phase of the study, patients with palpable invasive
      breast cancer underwent pre-operative supine MRI and optical scanning in the surgical
      position. In the second phase of the study, patients with non-palpable invasive breast cancer
      or DCIS who desire breast conservation will be randomized to either a usual care group, or a
      group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI)
      and undergoing breast cancer resection without the wire localization technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to use a novel technique (optical scanning) to correlate the supine MRI image to
      the surgical position in the OR and then to confirm and extend the Japanese study described
      above. In the first phase of the study, 5-25 patients with palpable invasive breast cancer
      will undergo pre-operative supine MRI and optical scanning in the surgical position. The
      purpose of this phase will be ensure that the images created from the optical
      scanner-adjusted supine MRI images closely correspond to the location of the palpable tumors
      in these breasts. All patients will then have their tumor resected using the standard method
      of either palpation or image guided wire localization. The first phase has been completed.

      In the second phase of the study, patients with non-palpable invasive breast cancer or DCIS
      who desire breast conservation will be randomized to either a usual care group, or a group
      receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and
      undergoing breast cancer resection without the wire localization technique.

      Our secondary objectives will be to determine:

        1. whether there are differences between the two groups in the volume of breast tissue
           removed.

        2. whether diagnostic information obtained from a supine MRI is equivalent to that obtained
           from the prone MRI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor.</measure>
    <time_frame>From baseline MRI to intraoperative measurements: 30 days</time_frame>
    <description>Mean calculated from differences in precise distances from the nipple to the superior, inferior, medial and lateral edges of the tumor as determined from the adjusted MRI images and conventional MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Determine Whether the Addition of Supine MRI to Conventional Imaging With Mammography and Prone MRI Results in a Lower Positive Margin Rate in Patients Undergoing Breast-conserving Surgery.</measure>
    <time_frame>30 days from surgery</time_frame>
    <description>The primary analysis consists of computing the positive margin rate observed in the two groups and comparing them with a chi-squared test and finally comparing the proportion of patients with positive margins in the two groups based on study criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences Between the Two Groups in the Volume of Breast Tissue Removed</measure>
    <time_frame>30 days from surgery</time_frame>
    <description>The mean specimen volumes to be compared using t - statistics. The concordance between lesion volumes identified on the supine MRI images and the prone MRI images will be evaluated through correlation and regression analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 addition of supine MRI to conventional imaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 randomize to SOC vs supine MRI + SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supine MRI</intervention_name>
    <description>A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.</description>
    <arm_group_label>Arm 1 addition of supine MRI to conventional imaging</arm_group_label>
    <arm_group_label>Arm 2 randomize to SOC vs supine MRI + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Phase 1

          1. Age greater than/equal to 18 years

          2. Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ

          3. Patient desire to undergo breast surgery

        3. Patients will have provided informed consent to participate, documented by their
        signature on the study consent form 4. The cancer enhances on breast MRI imaging.

        Inclusion Criteria Phase 2

          1. Age greater than/equal to 18 years

          2. Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ

          3. The tumor is visible and enhances on prone MRI and is &gt;1 cm in greatest diameter.

          4. . Determination by the surgeon that the neoplasm is non-palpable.A patient with a
             palpable hematoma from core biopsy, but a non-palpable neoplasm, will be eligible for
             study

          5. Patient desire to undergo breast conserving surgery

          6. Patients will have provided informed consent to participate, documented by their
             signature on the study consent form.The process of informed consent will be documented
             in the medical record and a copy of the signed consent form will be given to the
             patient.

        Exclusion Criteria (Phases 1 and 2)

          1. Absolute contraindication to MRI, including presence of implanted electrical device
             (pacemaker or neurostimulator), aneurysm clip or metallic foreign body in or near eyes

          2. Severe claustrophobia

          3. Contraindication to use of gadolinium based intravenous contrast, including life
             threatening allergy or compromised renal function (creatinine &gt; 2.0)

          4. History of median sternotomy

          5. Pregnancy (Patient attestation that they are not pregnant will be acceptable, as per
             standard, as per standard policy for MRIs at DHMC).

          6. Multicentric breast cancer, defined as two or more tumors in different quadrants of
             the breast. An eligibility worksheet will be completed for each patient prior to
             enrollment and will be signed and dated by the surgeon investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>April 8, 2019</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Richard J. Barth,Jr.</investigator_full_name>
    <investigator_title>Section Chief, General Surgery</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Conserving Surgery</keyword>
  <keyword>Breast diagnostics</keyword>
  <keyword>Breast imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT01929395/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants from Phase 1 participated in Phase 2</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Addition of Supine MRI to Conventional Imaging</title>
          <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
        </group>
        <group group_id="P2">
          <title>Phase 2: Addition of Supine MRI to Conventional Imaging</title>
          <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
        </group>
        <group group_id="P3">
          <title>Phase 2: Conventional Imaging (SOC)</title>
          <description>Wire localized (group WL) partial mastectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not complete - non-related toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Fail</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Addition of Supine MRI to Conventional Imaging</title>
          <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
        </group>
        <group group_id="B2">
          <title>Phase 2: Addition of Supine MRI to Conventional Imaging</title>
          <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
        </group>
        <group group_id="B3">
          <title>Phase 2: Conventional Imaging (SOC)</title>
          <description>Wire localized (group WL) partial mastectomy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor.</title>
        <description>Mean calculated from differences in precise distances from the nipple to the superior, inferior, medial and lateral edges of the tumor as determined from the adjusted MRI images and conventional MRI.</description>
        <time_frame>From baseline MRI to intraoperative measurements: 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Addition of Supine MRI to Conventional Imaging</title>
            <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor.</title>
          <description>Mean calculated from differences in precise distances from the nipple to the superior, inferior, medial and lateral edges of the tumor as determined from the adjusted MRI images and conventional MRI.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Determine Whether the Addition of Supine MRI to Conventional Imaging With Mammography and Prone MRI Results in a Lower Positive Margin Rate in Patients Undergoing Breast-conserving Surgery.</title>
        <description>The primary analysis consists of computing the positive margin rate observed in the two groups and comparing them with a chi-squared test and finally comparing the proportion of patients with positive margins in the two groups based on study criteria.</description>
        <time_frame>30 days from surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Addition of Supine MRI to Conventional Imaging</title>
            <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Conventional Imaging (SOC)</title>
            <description>Wire localized (group WL) partial mastectomy</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Whether the Addition of Supine MRI to Conventional Imaging With Mammography and Prone MRI Results in a Lower Positive Margin Rate in Patients Undergoing Breast-conserving Surgery.</title>
          <description>The primary analysis consists of computing the positive margin rate observed in the two groups and comparing them with a chi-squared test and finally comparing the proportion of patients with positive margins in the two groups based on study criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences Between the Two Groups in the Volume of Breast Tissue Removed</title>
        <description>The mean specimen volumes to be compared using t - statistics. The concordance between lesion volumes identified on the supine MRI images and the prone MRI images will be evaluated through correlation and regression analysis.</description>
        <time_frame>30 days from surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Addition of Supine MRI to Conventional Imaging</title>
            <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Conventional Imaging (SOC)</title>
            <description>Wire localized (group WL) partial mastectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Differences Between the Two Groups in the Volume of Breast Tissue Removed</title>
          <description>The mean specimen volumes to be compared using t - statistics. The concordance between lesion volumes identified on the supine MRI images and the prone MRI images will be evaluated through correlation and regression analysis.</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="33.9"/>
                    <measurement group_id="O2" value="69.8" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the inception of Phase 1 (baseline) to end of intervention for Phase 2: 7 years</time_frame>
      <desc>Regular investigator assessment and regular laboratory testing</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: Addition of Supine MRI to Conventional Imaging</title>
          <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
        </group>
        <group group_id="E2">
          <title>Phase 2: Addition of Supine MRI to Conventional Imaging</title>
          <description>Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)</description>
        </group>
        <group group_id="E3">
          <title>Phase 2: Conventional Imaging (SOC)</title>
          <description>Wire localized (group WL) partial mastectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Richard J. Barth Jr.</name_or_title>
      <organization>Dartmouth Hitchcock Medical Center</organization>
      <phone>(603) 650-9479</phone>
      <email>Richard.J.Barth.Jr@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

